Every intervention Outliyr has scored for liver health, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for liver health; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
47 of 105 evaluated interventions score 3.0+ out of 10 for liver health · 16 comparisons
Tirzepatide's dual GIP/GLP-1 agonism lowers hepatic fat by improving glycemic control and promoting visceral fat loss, mechanisms that align with the metabolic roots of liver disease. The evidence tier is moderate, derived…
Its single most-proven use is hepatoprotection: as the FDA antidote for acetaminophen overdose it cuts hepatotoxicity to about 6.1 percent when started within 10 hours versus 26.4 percent at 10 to 24…
Rosenstock 2023 supports the strongest part of the claim. The existing rationale points to this narrower claim: The glucagon receptor arm is designed to raise hepatic fat oxidation, and this verified source…
Soh 2024 anchors the most relevant signal. Glycine fits liver detox because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The score stays bounded because…
Yan 2015 tested berberine in NAFLD, and Nie 2024 pooled 10 RCTs in 811 NAFLD patients with improvements in liver enzymes, lipids, insulin resistance, BMI, and steatosis-related markers. Use the term liver…
Sanyal 2025 strengthened the phase 3 MASH case after Newsome 2021 showed NASH-resolution benefit. The phrase liver-detox is imperfect here; this is really metabolic liver disease improvement. Weight loss, insulin improvement, and…
Tian 2025 anchors the most relevant signal. Thymosin Alpha-1 fits liver detox when immune modulation is medically relevant and monitored rather than casually guessed. The score stays bounded because the best evidence…
The evidence points to a plausible use case without proving a universal response. Eshaghhosseiny Z et al. 2024 is the best anchor here because it reports 10 clinical studies and 408 women…
Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Tzang 2024 points in the same direction, but route, dose, baseline status,…
Kang 2011 reports Hydrogen-rich water improved quality-of-life and oxidative-stress direction during liver-tumor radiotherapy without reducing tumor response. Ohta 2011 points in the same direction, but route, dose, baseline status, and outcome tracking…
Vasireddi 2025 anchors the most relevant signal. BPC-157 fits liver detox when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The…
The most direct human evidence concerns hepatobiliary disease, bile acids, and liver-related endpoints rather than vague detox language. Pan 2013 studied TUDCA in liver cirrhosis, and Larghi 1997 provides PBC crossover context…
HIV-associated fatty liver data support a meaningful liver-fat signal. Stanley 2019 tested tesamorelin in HIV-associated NAFLD, and Fourman 2020 reported hepatic transcriptomic changes consistent with less inflammatory and fibrotic signaling. The score…
Liver disease is survodutide's strongest case. In a 48-week biopsy-confirmed Phase 2 trial, 62% of patients on 4.8 mg saw their fatty liver disease (MASH) improve with no worsening of scarring, versus…
The evidence points to a plausible use case without proving a universal response. Abuknesha et al. 2025 is the best anchor here because it reports 34 randomized trials, 114,326 participants and atrial…
Detoxification is the strongest single sulforaphane signal in humans. Egner 2014 Qidong RCT in 291 Chinese adults showed urinary benzene conjugate excretion increased 61 percent and acrolein conjugate excretion increased 23 percent…
Yarmohammadi 2021 pooled 8 RCTs and found AST fell 9.15 U/L (95% CI -16.09 to -2.21), a significant signal, while ALT and ALP did not move significantly. In NAFLD specifically, Ebrahimi-Mameghani 2014…
The liver holds the body's highest glutathione concentration and runs the Phase II conjugation that glutathione enables. The most direct human signal is Honda 2017, an open-label NAFLD pilot where oral glutathione…
Liver fat clearance is the most differentiated thing mazdutide does. Reported reductions run roughly 72 to 80 percent in participants with high baseline liver fat, with the GLORY-1 high-baseline subgroup near 80…
Vabishchevich 2026 supports direction more than certainty. The existing rationale points to this narrower claim: Zone 2 can reduce hepatic fat through improved insulin sensitivity and energy balance, making it relevant for…
The NAFLD signal is suggestive but thin. Mazloomi 2022 ran a randomized double-blind trial in 46 NAFLD patients using 20 g/day for 8 weeks and reported significant between-group improvement in ALT, AST,…
Metformin directly suppresses hepatic gluconeogenesis, so it influences liver metabolism, but the data do not demonstrate a broad detoxifying effect. The modest score acknowledges that benefits for MASLD or NAFLD appear only…
The existing rationale points to this narrower claim: this verified source supports liver fibrosis and hepatocellular-carcinoma prevention mechanisms in animals through autophagy, but there are no human liver-outcome RCTs. That does not…
Hagiyama 2024 reports 12 RCTs; 622 patients; low-certainty improvement in patient-reported outcomes and very-low-certainty strength signal after lower-limb surgeries. Wittholz 2024 points in the same direction, but route, dose, baseline status, and…
The existing rationale points to this narrower claim: No direct liver-detox evidence. AKG participates in nitrogen and amino-acid metabolism, but that does not equal a liver-detox outcome. That does not make Ca-AKG…
Zhou 2018 found Pinus massoniana pollen polysaccharides lowered AST, ALT, ALP, and MDA dose-dependently in CCl4-challenged rats, and Gok 2021 reported that Pinus brutia pollen extract cut ALT, AST, ALP, and bilirubin…
The evidence base for SLU-PP-332 liver-detox is limited to a single pre-clinical study that reported a roughly 20 % improvement in hepatic steatososis markers in mice with metabolic syndrome Billon 2024. ERR…
No direct liver-detox evidence. Circulation and sweating claims should not be translated into liver clearance or toxin-elimination claims.
The NAC component is the proven antidote that restores hepatic glutathione in acetaminophen overdose, validating the detoxification pathway, but GlyNAC as a combination has no dedicated liver-outcome trial, so the case rests…
Liver enzymes were stable to improved in human dosing studies, and ergothioneine concentrates in the liver, but dedicated hepatic-outcome trials are absent. No detox framing.
Preserved v0.x score. Detox positioning is not supported by verified clinical outcomes. Mechanistic liver-protection ideas come from oxidative-preconditioning literature summarized by Sagai and Bocci 2011, but no human trial in the audit…
There is an irony here. Curcumin improves liver enzymes and fat markers in NAFLD trials, yet enhanced-absorption forms are the ones linked to rare idiosyncratic liver injury. For fatty-liver support the signal…
INSUFFICIENT_EVIDENCE for liver detoxification; hepatic enzymes are monitoring targets because of metabolism and safety, not expected benefit.
Whole-food intake is protective; concentrated EGCG extracts are the caveat. Avoids detox framing.
The MASLD meta-analysis by Arslan 2025 suggests preliminary liver enzyme, lipid, and inflammation improvements with quercetin in MASLD adults, but the synthesis is new and study counts and bias profiles are still…
Hepatoprotective preclinical data exists, but human liver-outcome evidence remains weak and v1.0 avoids detox framing.
Modest, indirect liver benefit through weight loss and falling ALT, but no dedicated fatty-liver program.
Liver and detox claims remain weak. Akbari 2020 found no significant effect on ALT or AST in metabolic-syndrome-related RCTs, despite a small total-cholesterol signal and increased GGT. Human NAFLD translation has been…
Modern testosterone routes avoid the severe hepatotoxicity associated with older methylated oral anabolic steroids. Still, liver enzymes, lipids, alcohol use, and product selection need monitoring, especially with oral formulations.
A dedicated medicinal-chemistry program built BAM15-class uncouplers for nonalcoholic steatohepatitis and reduced liver fat and inflammation in mouse models (Childress et al. 2020). No human liver data.
A small calcium-butyrate trial in metabolic-associated fatty liver showed some benefit, but it is underpowered and not replicated.
Exercise improves hepatic fat metabolism and metabolic health, but the report avoids detox language beyond liver-fat and metabolic markers.
LiverTox lists Tongkat Ali as a rare possible cause of clinically apparent liver injury, while standardized-extract trials have not shown consistent liver-enzyme problems. This is a caution score, not a detox claim.
Hepatoprotective signals are preclinical only; no human liver-outcome evidence and v2.0 avoids detox framing.
Hataguchi 2005 noted lower hair levels of toxic minerals, but this is not a controlled detoxification endpoint and the report avoids detox framing.
Hepatoprotective preclinical data for chaga and reishi triterpenes, but the one notable human liver signal is a fatal powdered-reishi hepatitis case report, so the human picture is cautionary, not protective.
The TANGO trial (Chooi 2024, n=88, 12 weeks) supports an Asian-adapted Mediterranean diet for fatty liver and suggests C15:0 may add a small adjunctive signal, including LDL-cholesterol and gut-microbiome shifts.
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 12 of 47 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| Tirzepatide | $299–$449 | 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg | Prescription |
| NAC (N-Acetylcysteine) | $5–$15 | 600 to 1,200 mg/day | Over the counter |
| Retatrutide | $130–$960 | 2 mg, then 4 mg, then 8 mg or 12 mg weekly depending on protocol and tolerability | Research use only |
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| Berberine | $15–$25 | 500 mg berberine HCl three times daily with meals | Over the counter |
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Thymosin Alpha-1 | $100–$400 | 1.6 mg subcutaneous | Prescription |
| Ketogenic Diet | $100 | Standard keto, 40-50 g total carbohydrate/day | Over the counter |
| Taurine | $3–$10 | 1-3 g, 30-60 minutes before sleep | Over the counter |
| Molecular Hydrogen | Not priced yet | ||
| BPC-157 | $40–$80 | 250 to 500 mcg SC 1 to 2x/day near injury site | Grey market |
| TUDCA (Tauroursodeoxycholic Acid) | $12–$91 | 500-1,750 mg | Over the counter |
| Tesamorelin | $250–$500 | 2 mg subcutaneous daily in the evening | Prescription |
| Survodutide (BI 456906) | $300–$500 | 2.4, 4.8, or 6.0 mg | Research use only |
| Omega-3 | $20–$40 | 1-2 g/day combined EPA+DHA | Over the counter |
| Sulforaphane | $25–$60 | Broccoli sprout extract delivering about 150 micromoles sulforaphane per day | Over the counter |
| Chlorella | $10–$50 | 5-10 g/day | Over the counter |
| Glutathione (GSH) | $20–$45 | 1,000 mg/day | Over the counter |
| Mazdutide (IBI362) | $400–$420 | Step up over several weeks to 6 mg | Grey market |
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Spirulina | $10–$25 | 1 to 4.5 g/day | Over the counter |
| Metformin | $4–$30 | 500 mg with dinner for 1 week, then 500 mg twice daily for 1 week, then increase by 500 mg/week toward 1000 mg twice daily as tolerated | Prescription |
| Spermidine | $40–$90 | 1-3 mg/day oral WGE | Over the counter |
| Essential Amino Acids | Not priced yet | ||
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| Pine Pollen | $20–$45 | 5 to 10 g powder per day | Over the counter |
| SLU-PP-332 | $30–$80 | 3-5 mg/day oral | Research use only |
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| GlyNAC (Glycine + N-Acetylcysteine) | $10–$30 | Glycine and NAC at ~100 mg/kg/day each | Over the counter |
| Ergothioneine | Not priced yet | ||
| Ozone Therapy | $520–$2,600 | 20-30 mcg/mL ozone, roughly 1,000-1,500 mcg total per session | In clinic |
| Curcumin | $15–$40 | 500 mg curcuminoids | Over the counter |
| Rapamycin | $15–$50 | 3 mg | Prescription |
| Polyphenols (Dietary) | Not priced yet | ||
| Quercetin | $20–$50 | 200 mg/day | Over the counter |
| Astaxanthin | Not priced yet | ||
| Orforglipron (Foundayo) | $149–$299 | Start low, step up to 36 mg | Prescription |
| Resveratrol | Not priced yet | ||
| TRT (Testosterone Replacement Therapy) | $50–$300 | Clinician-selected formulation at the lowest dose likely to restore physiologic testosterone | Prescription |
| BAM15 | Not priced yet | ||
| Sodium Butyrate | Not priced yet | ||
| Norwegian 4×4 | Not priced yet | Over the counter | |
| Tongkat Ali | $20–$40 | 200 mg/day Physta standardized extract | Over the counter |
| Fucoidan (Brown Seaweed Polysaccharide) | Not priced yet | ||
| Quinton Marine Plasma (Seawater Minerals) | Not priced yet | ||
| Adaptogenic Mushrooms (Reishi, Cordyceps, Chaga) | $15–$40 | 1.5 to 1.8 g/day standardized extract | Over the counter |
| C15 (Pentadecanoic Acid) | $40–$50 | 200 mg/day | Over the counter |
Head-to-head reports and category rankings that name a winner on this use case.
This page ranks by the live body-composition subrating, not the overall BioHarmony score, since body composition is the goal this category is built around. Tirzepatide leads both measures.…
No. Berberine scores 6.5–7.0/10 and semaglutide 6.0–6.5/10, and that gap misleads almost everyone who reads it. Berberine scores higher because it is cheap, oral and easy to stop,…
BPC-157 for structural repair, KPV for inflammation you cannot afford to stimulate. BPC-157 scores gut health 9.0–9.5/10 against KPV's 7.0–7.5/10 and wins nearly every other row, because it…
No. Omega-3 scores 6.5–7.0/10 and C15:0 3.0/10, and the evidence behind the two is not close. C15:0 has two small human trials. Omega-3 has outcome trials, prescription forms…
Tesamorelin, unless price is the only thing deciding. It is FDA-approved for visceral fat with Phase 3 trials behind it, while CJC-1295 is a gray-market research peptide whose…
Different jobs, same shelf. Quercetin scores 6.5–7.0/10 and curcumin 5.5–6.0/10, and that gap is the liver-safety signal rather than a difference in effect. Curcumin wins joints, inflammatory markers,…
On weight loss they tie, and neither is a drug you can legitimately buy. Both score 7.5/10 for body composition, and both are investigational Lilly molecules with phase…
Sulforaphane scores 6.5–7.0/10 and glutathione 6.0–6.5/10, and both have a delivery problem. Sulforaphane needs active myrosinase or you absorb half as much. Plain oral glutathione barely raises blood…
Different liver problems. NAC scores 8.0–8.5/10 and TUDCA 6.5–7.0/10, and NAC wins liver detox 8.0–8.5/10 against 6.5–7.0/10, but its liver evidence is toxin and oxidative damage. TUDCA owns…
Metformin scores 6.5–7.0/10 and berberine 6.5–7.0/10, so the gap is meaningless. Metformin owns blood sugar with decades of outcome trials behind it. Berberine owns fatty liver, needs no…
NAC scores 8.0–8.5/10 and glutathione 6.0–6.5/10, and that gap is real. NAC is the cheaper upstream precursor with a six-decade clinical record, so start there. Glutathione earns its…
Start tirzepatide. It scores 6.0–6.5/10 against retatrutide's 5.5–6.0/10, and the gap is mostly availability and evidence maturity rather than weaker biology. Retatrutide is not approved anywhere, cannot legally…
Tirzepatide, at 8.0–8.5 out of 10 for liver health. Tirzepatide's dual GIP/GLP-1 agonism lowers hepatic fat by improving glycemic control and promoting visceral fat loss, mechanisms that align with the metabolic roots of liver disease.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 7.5–8.0 out of 10 for liver health.
C15 (Pentadecanoic Acid) scores 3.0–3.5 out of 10 for liver health but only 3.0–3.5 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
47 of the 105 interventions evaluated for liver health score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
